Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

  • This share is currently suspended. It was suspended at a price of 0.75
  • There is currently no data for BELL

Update re Proposed Fundraise

28 Oct 2025 17:32

RNS Number : 1868F
Belluscura PLC
28 October 2025
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

28 October 2025

 

Belluscura plc

("Belluscura" or the "Company")

 

Belluscura LLC Update

 

Belluscura plc (AIM: BELL), a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies, announced on 12 September 2025 that having previously terminated discussions with Omaha Value, Inc. and AI Ventures, Inc (together the "Omaha Investor Group") regarding a proposal to refinance the Company, those discussions had been revived in order to consider a revised and detailed proposition from the Omaha Investor Group. The Company remains in protracted discussions with the Omaha Investor Group but funding has not yet been confirmed and there can be no certainty that the funding will be secured.

 

In the meantime, given the rate of progress on the proposed refinancing, Sallyport Commercial Finance ("Sallyport"), the secured funder of the Company's wholly-owned US trading subsidiary Belluscura LLC, has foreclosed on the facility and the Company's directors have been notified of the disposal of the collateralised assets of Belluscura LLC to a third party, which is unconnected to the Company or the directors. Those assets comprised principally various items of physical stock, intellectual property and various customer and distributor details and databases. The sale did not include the intellectual property licensed from Separation Design Group, LLC, which comprises the principal IP behind the Company's portable oxygen concentrators. Sallyport has now been repaid in full and further accounts receivable will now flow into Belluscura LLC. 

 

Given the scale of Belluscura LLC's remaining liabilities the Board anticipates that without the proposed refinancing from the Omaha Investor Group, Belluscura LLC will be required to file for Chapter 7 under the U.S. Bankruptcy Code. The bankruptcy of Belluscura LLC would constitute an event of default under certain of the Company's and Belluscura LLC's existing contractual arrangements including, without limitation, the existing convertible loan notes issued by the Company.

 

A further announcement will be made in due course.

 

 

 

For further information please contact:

 

Belluscura plc

Tel: +44 (0)20 3128 8100

Paul Tuson, Chairman

 

SPARK Advisory Partners Limited

Nominated Adviser

Neil Baldwin

Tel: +44 (0)20 3368 3550

 

Dowgate Capital Limited

Joint Broker

Russell Cook / Daniel Ingram

Tel: +44 (0)20 3903 7715

 

Allenby Capital Limited

Joint Broker

Guy McDougall / Amrit Nahal (Sales and Corporate Broking)

Jeremy Porter / Lauren Wright (Corporate Finance)

 

Tel: +44 (0)20 3328 5656

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDPKFBBOBDDFKB
Date   Source Headline
2nd Jul 20242:30 pmRNSConditional placing of unsecured CLNs
1st Jul 20242:10 pmRNSTotal Voting Rights
27th Jun 20247:00 amRNSFinal Results
25th Jun 20243:34 pmRNSHolding(s) in Company
24th Jun 20247:00 amRNSUpdate re proposed placing of CLNs
14th Jun 20241:45 pmRNSPosting of Circular and Notice of General Meeting
12th Jun 20247:00 amRNSTrading update and proposed placing
17th Apr 20247:00 amRNSBelluscura Concert Party
11th Apr 202410:23 amRNSHolding(s) in Company
8th Apr 20241:15 pmRNSHolding(s) in Company
5th Apr 20243:48 pmRNSIssue of Equity
2nd Apr 20247:00 amRNSTrading Update
28th Mar 20247:00 amRNSTotal Voting Rights
8th Mar 20244:36 pmRNSOffer Closed
7th Mar 20248:30 amRNSCancellation of Listing and trading
4th Mar 20247:00 amRNSAcceptances level
26th Feb 20247:00 amRNSAcceptances level
22nd Feb 20243:00 pmRNSAcceptances level, issue of equity & AIM Admission
19th Feb 20247:00 amRNSAcceptances level & offer closing
15th Feb 20243:51 pmRNSAcceptances level, issue of equity & AIM Admission
13th Feb 20247:00 amRNSDistribution Agreement & New VP North America
13th Feb 20247:00 amRNSAcceptances Level
12th Feb 20241:44 pmGNWForm 8.3 - Belluscura PLC
9th Feb 20248:16 amRNSOffer becomes wholly unconditional
8th Feb 20243:31 pmRNSAcceptances level, issue of equity & AIM Admission
7th Feb 20244:20 pmRNSOffer Unconditional (subject to AIM Admission)
7th Feb 202411:13 amRNSForm 8.3 - Belluscura Plc
5th Feb 20241:30 pmRNSResult of General Meeting
5th Feb 20247:00 amRNSAcceptances received in respect of the Offer
2nd Feb 202411:24 amRNSForm 8 (OPD) Belluscura plc
2nd Feb 202411:18 amRNSForm 8 (OPD) TMT Acquisition plc
1st Feb 20246:16 pmRNSForm 8 (OPD) TMT Acquisition plc - Amended
1st Feb 20246:14 pmRNSForm 8 (OPD) Belluscura plc - Amended
1st Feb 20242:34 pmGNWForm 8.3 - Belluscura PLC
29th Jan 202411:42 amRNSForm 8.3 - Belluscura PLC
24th Jan 20246:24 pmRNSForm 8.3 - Belluscura PLC
24th Jan 20246:17 pmRNSForm 8.3 - Belluscura
24th Jan 20246:02 pmRNSForm 8.3 - Belluscura PLC - Replacement
24th Jan 20245:49 pmRNSForm 8.3 - Belluscura PLC
24th Jan 20243:25 pmRNSForm 8.3 - Belluscura plc
24th Jan 20243:14 pmRNSHolding(s) in Company
24th Jan 202410:45 amRNSForm 8.3 - Belluscura Plc
23rd Jan 20246:06 pmRNSForm 8.3 - Belluscura plc
23rd Jan 20245:39 pmRNSForm 8.3 - BELLUSCURA PLC
19th Jan 20241:30 pmRNSPosting of Offer Document and Circular
8th Jan 20241:01 pmGNWForm 8.3 - Belluscura PLC
22nd Dec 202312:10 pmRNSExtension to deadline for posting Offer Document
20th Dec 20237:00 amRNSChinese registration and Trading Update
19th Dec 20231:04 pmGNWForm 8.3 - Belluscura PLC
13th Dec 20232:43 pmGNWForm 8.3 - Belluscura PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.